Introduction/Background Infection with Human Papillomavirus (HPV) is a significant concern among patients’ living with Human Immunodeficiency Virus (HIV), particularly due to the increased risk of persistent infection and cervical neoplasia. Understanding the prevalence and distribution of HPV genotypes in cervical samples from HIV-positive patients is essential for elucidating the impact on cervical disease.

Methodology It is a descriptive, retrospective study in which we analyzed a data base of 2200 patients with altered cervical cytology from Sant Joan de Deu Hospital in Barcelona. Thirty HIV-positive women were included. Pregnant patients were excluded.

Cervical specimens were obtained via triple-sampling conventional Pap smear adding VPH test from attending routine gynecological examinations or cervical screening programs. Cervical pap-smear was collected at 3–6-12 months to evaluate the cervical disease progression. We performed statistical analysis with SPPSS to calculate absolute and relative frequencies.

Results The most prevalent HPV genotypes among HIV-positive patients were high-risk (HR) HPV types other than 16/18 (56%), followed by HPV-16/18 (30%), and low-risk (LR) genotypes (4%). Biopsy assessments revealed that patients with HR-HPV types other than 16/18 had 23.5% negative biopsies, 41% with CIN1, and 35.2% with CIN 2–3; whereas HPV-16/18 showed 100% of biopsies with CIN 2–3. Comparison among these HPV groups (negative/LR-HPV/HR-HPV other than 16/18/HPV-16/18) and their cytological results yielded statistical significance (p = 0.02).

Co-infection with more than one HPV strain was notably prevalent, emphasizing the complex nature of HPV infections in this immunocompromised population.

Conclusion It has been observed that in HIV pacients HR-HPV no 16/18 is more frequent. However progression to high-grade biopsy is more lickely in VPH 16/18.

The analysis contributes to a comprehensive understanding of HPV-associated cervical pathology within this vulnerable population and aids in guiding tailored interventions and vaccination strategies. Further studies are necessary to add information to the protocols of tratments in this type of patients.

Disclosures .